Gene therapy for chronic traumatic brain injury: Challenges to resolve long-term consequences of brain damage

2021 ◽  
Vol 21 ◽  
Author(s):  
Vipin V. Dhote ◽  
Prem Samundre ◽  
Aman B. Upaganlawar ◽  
Aditya Ganeshpurkar

: The promise of gene therapy is alluring not only for CNS disorders but also for other pathological conditions. Gene therapy employs the insertion of a healthy gene into the identified genome to replace or replenish genes responsible for pathological disorder or damage due to trauma. The last decade has seen a sea change in the understanding of vital aspects of gene therapy. Despite the complexity of traumatic brain injury (TBI), the advent of gene therapy in various neurodegenerative disorders has reinforced the ongoing efforts of alleviating TBI-related outcomes with gene therapy. The review highlights the genes modulated in response to TBI and evaluates their impact on the severity and duration of the injury. We reviewed strategies that pinpointed the most relevant gene targets to restrict debilitating events of brain trauma and utilize vector of choice to deliver the gene of interest at the appropriate site. We attempted to summarize the long-term neurobehavioral consequences of TBI due to numerous pathometabolic perturbations associated with a plethora of genes. Herein, we shed light on the basic pathological mechanisms of brain injury, genetic polymorphism in individuals susceptible to severe outcomes, modulation of gene expression due to TBI, and identification of genes for their possible use in gene therapy. The review also provided insights on the use of vectors and challenges in translations of this gene therapy to clinical practices.

2015 ◽  
Vol 148 (4) ◽  
pp. S-384
Author(s):  
Elise L. Ma ◽  
Allen Smith ◽  
Neemesh Desai ◽  
Alan Faden ◽  
Terez Shea-Donohue

2020 ◽  
pp. 1-12
Author(s):  
Cindy Santiago-Castañeda ◽  
Marysol Segovia-Oropeza ◽  
Luis Concha ◽  
Sandra Adela Orozco-Suárez ◽  
Luisa Rocha

Background: Severe traumatic brain injury (TBI), an important risk factor for Alzheimer’s disease, induces long-term hippocampal damage and hyperexcitability. On the other hand, studies support that propylparaben (PPB) induces hippocampal neuroprotection in neurodegenerative diseases. Objective: Experiments were designed to evaluate the effects of subchronic treatment with PPB on TBI-induced changes in the hippocampus of rats. Methods: Severe TBI was induced using the lateral fluid percussion model. Subsequently, rats received subchronic administration with PPB (178 mg/kg, TBI+PPB) or vehicle (TBI+PEG) daily for 5 days. The following changes were examined during the experimental procedure: sensorimotor dysfunction, changes in hippocampal excitability, as well as neuronal damage and volume. Results: TBI+PEG group showed sensorimotor dysfunction (p <  0.001), hyperexcitability (64.2%, p <  0.001), and low neuronal preservation ipsi- and contralateral to the trauma. Magnetic resonance imaging (MRI) analysis revealed lower volume (17.2%; p <  0.01) and great damage to the ipsilateral hippocampus. TBI+PPB group showed sensorimotor dysfunction that was partially reversed 30 days after trauma. This group showed hippocampal excitability and neuronal preservation similar to the control group. However, MRI analysis revealed lower hippocampal volume (p <  0.05) when compared with the control group. Conclusion: The present study confirms that post-TBI subchronic administration with PPB reduces the long-term consequences of trauma in the hippocampus. Implications of PPB as a neuroprotective strategy to prevent the development of Alzheimer’s disease as consequence of TBI are discussed.


GeroScience ◽  
2020 ◽  
Author(s):  
Luca Toth ◽  
Andras Czigler ◽  
Peter Horvath ◽  
Balint Kornyei ◽  
Nikolett Szarka ◽  
...  

Abstract Traumatic brain injury (TBI) was shown to lead to the development of cerebral microbleeds (CMBs), which are associated with long term cognitive decline and gait disturbances in patients. The elderly is one of the most vulnerable parts of the population to suffer TBI. Importantly, ageing is known to exacerbate microvascular fragility and to promote the formation of CMBs. In this overview, the effect of ageing is discussed on the development and characteristics of TBI-related CMBs, with special emphasis on CMBs associated with mild TBI. Four cases of TBI-related CMBs are described to illustrate the concept that ageing exacerbates the deleterious microvascular effects of TBI and that similar brain trauma may induce more CMBs in old patients than in young ones. Recommendations are made for future prospective studies to establish the mechanistic effects of ageing on the formation of CMBs after TBI, and to determine long-term consequences of CMBs on clinically relevant outcome measures including cognitive performance, gait and balance function.


Neurology ◽  
2017 ◽  
Vol 89 (18) ◽  
pp. 1923-1925 ◽  
Author(s):  
Michael W. Weiner ◽  
Paul K. Crane ◽  
Thomas J. Montine ◽  
David A. Bennett ◽  
Dallas P. Veitch

Traumatic brain injury (TBI) commonly occurs in civilian and military populations. Some epidemiologic studies previously have associated TBI with an increased risk of Alzheimer disease (AD). Recent clinicopathologic and biomarker studies have failed to confirm the relationship of TBI to the development of AD dementia or pathologic changes, and suggest that other neurodegenerative processes might be linked to TBI. Additional studies are required to determine the long-term consequences of TBI.


2020 ◽  
Vol 46 (3) ◽  
pp. 15
Author(s):  
Y. V. Lekomtseva

Introduction. Mild traumatic brain injury (mTBI) was reported to be the most frequent among other types of brain injuries and is the main reason for the disability in mid-life and middleaged people. It’s known that antioxidants can reduce oxidative stress, so, to prevent secondary brain injury modulating maintaining of long-term consequences after mTBI. Purpose of the study. This work was to study the serum vitamin E, C and A levels in the patients with long-term consequences after mTBI to explore their potential pathogenetic influence. Materials and methods. Sixty-seven patients with long-term consequences after mTBI were investigated with the mean age of 43,61 ± 8,24 years (18 women, 26,86% and 49 men, 73,14%) where the vitamin E, C and A contents were measured in sera by spectrophotometer method using standard protocols and reagents (Sigma, USA).  Results. In this work, it was found descending serum levels of all investigated vitaminantioxidants in almost all patients with longterm consequences after mTBI where the content of vitamins A (M ± s: 1,63 ± 1,56 mkM/l) and E (25,41 ± 0,93 mkM/l) had a tendency to decreasing without significant differences compare to controls. It was found the statistically significant decreased of vitamin C levels in the serum samples of our investigated patients when compared to controls (p < 0,05, t = 4,59, 95% CI 98,81 to 55,68) where in the main patient group, the medians of total vitamin C level was 30,57 ± 5,38 mkM/l vs 36,91 ± 5,22 mkM/l in controls. It was shown that the patients with long-term consequences after mild contusion in anamnesis (64,18%) had the prominent changes in the vitamin C content. Conclusion. The maintaining of long-term consequences of mTBI was accompanied by the vitamin-antioxidant dyshomeostasis such as decreasing of vitamin C serum level associated with a tendency to decreasing of vitamins A and E levels that may play the certain role in the pathogenesis. All these data are needed to be accounted into the consideration during the treatment of this patient category. Keywords: long-term consequences of mild traumatic brain injury, vitamin-antioxidant homeostasis.


Sign in / Sign up

Export Citation Format

Share Document